Adamant Health
Ilkka Laurila is an experienced finance professional currently serving as Group CFO at Taaleri, a Nordic investment and asset manager, since February 2024. Laurila also holds multiple board positions, including Board Member at Linio Biotech, which focuses on biotechnology solutions, and Nightingale Health, a company dedicated to preventive healthcare. Additionally, Laurila is the Chairperson of the Board at Adamant Health Oy, a startup specializing in healthcare technology for movement disorders. Other roles include Board Member and Investor at Temepa Infra Oy, Owner of Penni-Invest Oy providing advisory services, and previous positions such as CFO at Plugit Finland and Interim CFO at Magsort Ltd. Laurila's education includes a Master's degree in Economics from LUT University and a Master's degree in Forestry from the University of Eastern Finland.
This person is not in the org chart
This person is not in any teams
Adamant Health
We are helping people with Parkinson's disease by providing an accurate and clear picture of their condition to get the best treatment possible, improving their quality of life. Adamant Health is a Finnish health-tech startup on a mission to revolutionize the care of Parkinson’s disease by enabling data-driven disease management, supporting earlier diagnosis and improving patient outcomes. The company was founded in 2020 as a spin-off from the University of Eastern Finland to bring our research-based, innovative technology to patients, clinicians, healthcare service providers and companies developing new therapies. We have developed the first, advanced precision technology able to measure the visible and invisible motor symptoms of Parkinson's disease. Our unique CE-marked data-analysis technology, based on surface electromyography (EMG) and motion measurement, provides detailed and accurate symptom data, essential for supporting personalized treatment that can be continuously optimized. Our technology is based on over 15 years of research with more than 25 scientific articles published in international publications. In addition to Parkinson's disease, our technology brings also visibility to the symptoms of various other movement disorders.